Association of clinical severity scores with psychosocial impact in patients with hidradenitis suppurativa

Jfri, Abdulhadi; Netchiporouk, Elena; Raymond, Katherine; Litvinov, Ivan V.; O’Brien, Elizabeth

doi:10.1016/j.jaad.2020.08.022

Cited by 8 publications

(8 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This multifactorial chronic inflammatory condition usually affects intertriginous areas of the body including the axilla, inframammary area, inguinal, perianal, gluteal, and pubic regions. This condition usually begins in the second or third decade of life cohering with substantial psychological and emotional burdens as well as physical comorbidity …”

Section: Introductionmentioning

confidence: 99%

“…1,2 This multifactorial chronic inflammatory condition usually affects intertriginous areas of the body including the axilla, inframammary area, inguinal, perianal, gluteal, and pubic regions. This condition usually begins in the second or third decade of life cohering with substantial psychological and emotional burdens 3,4 as well as physical comorbidity. [5][6][7] The estimated prevalence of HS shows wide variations, with a point prevalence ranging from 0.3% in Germany to 4.1% in Denmark owing to heterogeneous measurement methods and populations being studied.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of Hidradenitis Suppurativa

et al. 2021

View full text Add to dashboard Cite

IMPORTANCE Hidradenitis suppurativa/acne inversa (HS) is a chronic inflammatory skin disease characterized by occlusion of hair follicles as a primary pathogenic factor. There are scarce data regarding the prevalence of HS. OBJECTIVE To estimate overall HS prevalence.DATA SOURCES This review and meta-regression analysis was conducted using the Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guideline. The academic search included PubMed, Cochrane registry, ClinicalTrials.gov, and evidence by NHS UK and Trip databases from inception through May 2020. To analyze HS prevalence, only cross-sectional studies or baseline assessments of longitudinal cohorts using census-based surveys or probabilistic and nonprobabilistic epidemiologic methods were considered. The search terms were (prevalence OR incidence OR epidemiology) AND (hidradenitis suppurativa OR acne inversa OR Verneuil's disease). No language restriction was applied.STUDY SELECTION Original investigations that reported HS prevalence were included. After exclusion criteria were applied, 17 studies qualified for qualitative analysis, but only 16 studies were quantitatively assessed.DATA EXTRACTION AND MEASURES Two reviewers extracted data by age, diagnostic criteria, presence of any comorbidity, sample sizes, continent/location, sex, and other characteristics. Assessment of bias risk used the Joanna Briggs Institute Critical Appraisal Instrument for Studies Reporting Prevalence Data using random-effects models to synthesize available evidence.MAIN OUTCOMES AND MEASURES Hidradenitis suppurativa prevalence (with 95% CI) among the overall population and among subgroups. Between-study heterogeneity was assessed (Cochran Q statistic) and quantified (I 2 statistic). RESULTSIn 16 quantitatively assessed studies included, prevalence estimates were reported only from Western European and Scandinavian countries, the US, and Australia. Meta-analysis with random effects, after adjusting for publication bias in the prevalence estimates, revealed a 0.40% prevalence (95% CI, 0.26%-0.63%) for HS. Studies based on clinical samples revealed a higher pooled prevalence of HS (1.7%) than population-based studies (0.3%). CONCLUSIONS AND RELEVANCEThe findings of this systematic review and meta-regression analysis may help facilitate policy formulation, channeling funding and guiding principles for better disease diagnosis using universal valid tools and management.

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

Prevalence of Hidradenitis Suppurativa

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Since HS is associated with substantial physical, emotional, and psychological burdens, it is important to shed light on its epidemiology from both developed and developing countries as well. [11][12][13][14] Given the lack of literature on the epidemiology of HS from developing countries, we undertook a review of different domains of epidemiology such as prevalence, incidence, risk factors, outcomes, prognostic factors, and distribution across the globe.…”

Section: Introductionmentioning

confidence: 99%

Incidence, Risk Factors, and Prognosis of Hidradenitis Suppurativa Across the Globe: Insights from the Literature

Alotaibi¹

2023

CCID

View full text Add to dashboard Cite

Hidradenitis suppurativa, a chronic inflammatory disease of the skin, affects a patient’s quality of life to a greater extent. While the disease burden, including its incidence and prevalence, has been extensively studied in the western population, there is a paucity of data from developing countries on the epidemiology of Hidradenitis suppurativa. Therefore, a general literature review was conducted to shed light on the epidemiology of Hidradenitis suppurativa across the globe. We reviewed the most recently available information on epidemiology, including incidence, prevalence, risk factors, prognosis and quality of life, complications, and associated comorbid among patients with Hidradenitis suppurativa. The estimated global prevalence of Hidradenitis suppurativa is found to be 0.00033–4.1%, with a relatively higher prevalence of 0.7–1.2% in European and US populations. Both genetic and environmental factors are associated with Hidradenitis suppurativa. Patients with Hidradenitis suppurativa have associated comorbid such as cardiovascular disease, type II diabetes mellitus, mental health issues, and sleep and sexual dysfunctions. These patients spend poor quality of life and tend to be less productive. Future studies are needed to assess the burden of Hidradenitis suppurativa in developing countries. Since the disease tends to be underdiagnosed, future studies should rely on clinical diagnosis rather than self-reporting to avoid the potential of recall bias. Attention needs to be diverted to developing countries with less amount of data on Hidradenitis suppurativa.

show abstract

“…Due to painful and malodorous lesions, HS patients experience a significant impairment of their quality of life [3]. This decrease in quality of life is related to a greater severity of the disease, but it is also present in milder cases [4]. Many novel therapies for HS are being developed in recent years, but most of them are aimed at moderate or severe cases [5].…”

Section: Introductionmentioning

confidence: 99%

Topical 15% Resorcinol Is Associated with High Treatment Satisfaction in Patients with Mild to Moderate Hidradenitis Suppurativa

Beltrá-Picó

Sánchez-Pujol

Fuster-Ruiz-de-Apodaca

et al. 2021

Dermatology

View full text Add to dashboard Cite

Background: Topical 15% resorcinol is commonly used in clinical practice for the treatment of nodules and abscesses in patients with hidradenitis suppurativa (HS). It has been shown to be clinically effective in some small studies, but data on satisfaction perceived by patients are lacking. The Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 is a validated measure of patient satisfaction, evaluating four domains: effectiveness, side effects, convenience, and global satisfaction. Our objective was to obtain data from HS patients regarding resorcinol treatment satisfaction and its relationship with clinical and epidemiological variables. Methods: We performed a cross-sectional study providing TSQM version 1.4 questionnaires to HS patients who had been prescribed topical resorcinol during the previous 24 months. Results: Ninety-two patients answered the questionnaire. Eighty-five out of 92 (92.4%) were Hurley II and 7 Hurley I. The mean total score was 317.5 out of 400 (71.0 points in effectiveness, 93.6 in side effects, 79.3 in convenience, and 73.2 in global satisfaction). Total score was higher in men than in women (329.7 vs. 311.6, p = 0.026) and higher scores on convenience were seen in patients who were not overweight or obese (86.9 vs. 77.1, p = 0.016). Most patients (65, 70.6%) denied having any side effect. 78 (84.8%) of the patients would recommend the treatment. Conclusion: The results of this study suggest that HS patients treated with resorcinol 15% are very satisfied with this treatment.

show abstract

Association of clinical severity scores with psychosocial impact in patients with hidradenitis suppurativa

Cited by 8 publications

References 4 publications

Prevalence of Hidradenitis Suppurativa

Prevalence of Hidradenitis Suppurativa

Incidence, Risk Factors, and Prognosis of Hidradenitis Suppurativa Across the Globe: Insights from the Literature

Topical 15% Resorcinol Is Associated with High Treatment Satisfaction in Patients with Mild to Moderate Hidradenitis Suppurativa

Contact Info

Product

Resources

About